### Short-term Adherence – Oral Diabetes Medicines

**Purpose:** The purpose of this measure is to identify and track members who are late in filling an oral diabetes medicine.

| **Who is Included?** (denominator) | o Members with claims for single and multi-ingredient oral products used in the treatment of diabetes. Includes: sulfonylurea (e.g. glipizide), DPP-4 (e.g. sitagliptin), TZD (e.g. pioglitazone), biguanide (e.g. metformin), and alpha-glucosidase inhibitor (e.g. acarbose) |
| **What Pharmacy Claim Data is evaluated?** (numerator) | o Members who are between 20 and 100 days past their anticipated refill date |
| **When does the analysis occur?** | o Reviews claims from the previous 12 months  
o Updated Monthly |
| **Where can I get this information?** | o Monthly NaviNet report updates reflect Gaps In Care for PCP practice panel membership.  
o Quarterly printed reports sent to PCPs reflect Gaps In Care for PCP practice panel membership.  
o Panel membership results include indicators for this Gaps In Care measure as “At Risk” |
| **Why does my member have an “At Risk” status?** | o Pharmacy claims show an oral diabetes medicine is overdue for refill by 20 to 100 days. |

Available at: https://PartD.ProgramInfo.US/PatientSafety  
Last Updated on 02/06/2011

Revised: April 2013